Mesoblast Limited
Mesoblast Limited (MESO): 9 pipeline candidates · 3 upcoming catalysts · ~9 mo cash runway · 12 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.1 months
D/E 0.36 · 0% dilution
Lead: Approved
9 candidates
3 upcoming, next in ~744d
30 buys · 0 sells (180d)
A transparent, data-derived signal for Mesoblast Limitedacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$130.0M
Quarterly Burn
$50.0M
Runway
9.1 mo
Revenue
$17.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| diphenhydramine | — |
| prochymal | Phase 3 |
| prochymal | Phase 3 |
| prochymal adult human mesenchymal stem cells | Phase 3 |
| remestemcel-l | Phase 3 |
| remestemcel-l-rknd | Phase 3 |
| rexlemestrocel-l | Phase 3 |
| rexlemestrocel-l + ha mixture | Phase 3 |
| synojoynt | Approved |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
66
Total value held
$70.2M
| Holder | Shares | Value |
|---|---|---|
| jane street group, llc | 851,286 | $13.1M |
| susquehanna international group, llp | 714,572 | $11.0M |
| blackrock, inc. | 630,855 | $9.7M |
| citadel advisors llc | 545,359 | $8.4M |
| morgan stanley | 514,431 | $7.9M |
| goldman sachs group inc | 397,215 | $6.1M |
| bank of america corp /de/ | 100,004 | $1.5M |
| group one trading llc | 83,915 | $1.3M |
| m&g plc | 59,100 | $887K |
| lpl financial llc | 49,617 | $763K |
Showing top 10 of 66 institutional holders of Mesoblast Limited. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Mesoblast Limited's pipeline?
Mesoblast Limited (MESO) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Mesoblast Limited's next catalyst?
Mesoblast Limited's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Ad" — expected July 1, 2028.
What is Mesoblast Limited's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Mesoblast Limited has approximately 9.1 months of cash runway.
What is Mesoblast Limited's market capitalization?
Mesoblast Limited's market capitalization is approximately $1.8B.
Who is the CEO of Mesoblast Limited?
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) is the chief executive officer of Mesoblast Limited (MESO).
Get the full picture on Mesoblast Limited
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.